Date: 2013-02-08
Type of information:
Compound: therapeutic peptide
Company: Pergamum (Sweden) Cadila Pharmaceuticals (India)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease:
Details: Pergamum, a biopharmaceutical company specialized in the development of therapeutic peptides for local application in infections and wounds, and Cadila Pharmaceuticals have announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics. The two companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide that has been developed by Pergamum AB. The development will be conducted at the facilities of Cadila Pharmaceuticals in Ahmedabad, India. \"Pergamum has developed a new class of short synthetic peptides with both anti-infective and anti-inflammatory properties derived from the body’s own defense system. There is a rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with this novel therapeutic peptide”, says Jonas Ekblom, CEO of Pergamum.
\"This partnership combines Cadila’s advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration”, says Rajiv Modi, Chairman and Managing Director of Cadila Pharmaceuticals Ltd.
The establishment of this cooperation was facilitated by Dr. CB Sanjeevi of Karolinska Institutet and Business Sweden.
Financial terms: Cadila will be responsible for all costs related to the development of the product up to Phase II and global rights will be shared between the companies.
Latest news:
